Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
Abstract Olverembatinib (HQP1351) is a BCR‐ABL1 tyrosine kinase inhibitor with promising clinical activity. It is approved in China for the treatment of patients with chronic myeloid leukemia harboring drug‐resistant mutations, such as T315I. In vitro studies suggested that metabolism of olverembati...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Wiley
2024-09-01
|
| Seria: | Clinical and Translational Science |
| Dostęp online: | https://doi.org/10.1111/cts.70021 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|